Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:INMD NASDAQ:MDXG NASDAQ:SMTI NASDAQ:TNDM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeINMDInMode$15.030.0%$14.67$13.14▼$19.85$950.68M2.091.20 million shs100,988 shsMDXGMiMedx Group$7.17-1.3%$7.08$5.47▼$10.14$1.06B1.73671,345 shs37,358 shsSMTISanara MedTech$32.88+8.4%$31.27$23.53▼$39.08$292.63M1.2132,354 shs29,689 shsTNDMTandem Diabetes Care$14.83+2.1%$12.58$9.98▼$39.98$1.00B1.481.74 million shs107,177 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceINMDInMode-1.31%+0.87%+0.33%-1.31%-0.53%MDXGMiMedx Group-0.68%+4.01%+1.68%+4.31%+29.41%SMTISanara MedTech-2.98%-4.41%-9.65%+0.30%+2.50%TNDMTandem Diabetes Care-3.26%+19.60%+15.42%-8.39%-65.25%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeINMDInMode$15.030.0%$14.67$13.14▼$19.85$950.68M2.091.20 million shs100,988 shsMDXGMiMedx Group$7.17-1.3%$7.08$5.47▼$10.14$1.06B1.73671,345 shs37,358 shsSMTISanara MedTech$32.88+8.4%$31.27$23.53▼$39.08$292.63M1.2132,354 shs29,689 shsTNDMTandem Diabetes Care$14.83+2.1%$12.58$9.98▼$39.98$1.00B1.481.74 million shs107,177 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceINMDInMode-1.31%+0.87%+0.33%-1.31%-0.53%MDXGMiMedx Group-0.68%+4.01%+1.68%+4.31%+29.41%SMTISanara MedTech-2.98%-4.41%-9.65%+0.30%+2.50%TNDMTandem Diabetes Care-3.26%+19.60%+15.42%-8.39%-65.25%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceINMDInMode 2.00Hold$18.0420.05% UpsideMDXGMiMedx Group 2.50Moderate Buy$12.0067.41% UpsideSMTISanara MedTech 2.33Hold$50.0052.07% UpsideTNDMTandem Diabetes Care 2.24Hold$22.6952.98% UpsideCurrent Analyst Ratings BreakdownLatest SMTI, MDXG, TNDM, and INMD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/7/2025TNDMTandem Diabetes CareCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral$11.00 ➝ $15.009/29/2025INMDInModeZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold9/29/2025TNDMTandem Diabetes CareCanaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$24.009/27/2025INMDInModeWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D+)9/27/2025MDXGMiMedx GroupWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)9/27/2025SMTISanara MedTechWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025TNDMTandem Diabetes CareWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/8/2025TNDMTandem Diabetes CareOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$44.00 ➝ $22.008/21/2025TNDMTandem Diabetes CareCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$10.35 ➝ $11.008/18/2025SMTISanara MedTechHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$53.00 ➝ $54.008/18/2025SMTISanara MedTechHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$53.00 ➝ $54.00(Data available from 10/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookINMDInMode$394.82M2.41$1.80 per share8.35$10.12 per share1.49MDXGMiMedx Group$348.88M3.04$0.32 per share22.06$1.31 per share5.47SMTISanara MedTech$86.67M3.38N/AN/A$4.45 per share7.39TNDMTandem Diabetes Care$940.20M1.07N/AN/A$4.01 per share3.70Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateINMDInMode$181.27M$2.476.098.26N/A44.50%18.38%16.35%10/29/2025 (Estimated)MDXGMiMedx Group$42.42M$0.2134.1422.40N/A8.84%23.03%17.09%10/29/2025 (Estimated)SMTISanara MedTech-$9.66M-$1.16N/AN/AN/A-10.22%-26.43%-10.69%11/12/2025 (Estimated)TNDMTandem Diabetes Care-$96.03M-$3.09N/AN/AN/A-20.51%-65.40%-13.87%11/6/2025 (Estimated)Latest SMTI, MDXG, TNDM, and INMD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails10/29/2025Q3 2025INMDInMode$0.32N/AN/AN/A$88.05 millionN/A10/29/2025Q3 2025MDXGMiMedx Group$0.07N/AN/AN/A$94.74 millionN/A8/13/2025Q2 2025SMTISanara MedTech-$0.33-$0.23+$0.10-$0.23$25.15 million$25.83 million8/6/2025Q2 2025TNDMTandem Diabetes Care-$0.40-$0.48-$0.08-$0.78$238.39 million$240.68 million7/30/2025Q2 2025INMDInMode$0.50$0.47-$0.03$0.42$98.45 million$95.60 million7/30/2025Q2 2025MDXGMiMedx Group$0.06$0.10+$0.04$0.06$90.79 million$98.61 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthINMDInModeN/AN/AN/AN/AN/AMDXGMiMedx GroupN/AN/AN/AN/AN/ASMTISanara MedTechN/AN/AN/AN/AN/ATNDMTandem Diabetes CareN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioINMDInModeN/A9.608.58MDXGMiMedx Group0.084.393.90SMTISanara MedTech1.252.262.03TNDMTandem Diabetes Care2.322.441.88Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipINMDInMode68.04%MDXGMiMedx Group79.15%SMTISanara MedTech8.10%TNDMTandem Diabetes CareN/AInsider OwnershipCompanyInsider OwnershipINMDInMode6.92%MDXGMiMedx Group1.70%SMTISanara MedTech42.60%TNDMTandem Diabetes Care1.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableINMDInMode48063.21 million58.84 millionOptionableMDXGMiMedx Group870147.96 million145.44 millionOptionableSMTISanara MedTech608.90 million5.11 millionNot OptionableTNDMTandem Diabetes Care2,65067.57 million66.29 millionOptionableSMTI, MDXG, TNDM, and INMD HeadlinesRecent News About These CompaniesCitigroup Maintains Tandem Diabetes Care (TNDM) Neutral RecommendationOctober 8 at 2:40 AM | msn.comTNDM Investor News: If You Have Suffered Losses in Tandem Diabetes Care, Inc. (NASDAQ: TNDM), You Are Encouraged to Contact The Rosen Law Firm About Your RightsOctober 6 at 1:42 PM | globenewswire.comTandem Diabetes Care (NASDAQ:TNDM) Shares Up 7.7% - Here's What HappenedOctober 3, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tandem Diabetes Care, Inc. - TNDMOctober 3, 2025 | prnewswire.comTandem Diabetes Care, Inc. (NASDAQ:TNDM) Given Consensus Rating of "Hold" by BrokeragesOctober 3, 2025 | marketbeat.comagilon health, Tandem Diabetes, NeoGenomics, Hims & Hers Health, and Oscar Health Stocks Trade Up, What You Need To KnowOctober 2, 2025 | msn.comTandem Diabetes Care to Announce Third Quarter 2025 Financial Results on November 6, 2025October 2, 2025 | businesswire.comSecurities Fraud Investigation Into Tandem Diabetes Care, Inc. (TNDM) Continues – Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law FirmOctober 1, 2025 | globenewswire.comTNDM Investor News: If You Have Suffered Losses in Tandem Diabetes Care, Inc. (NASDAQ: TNDM), You Are Encouraged to Contact The Rosen Law Firm About Your RightsSeptember 30, 2025 | globenewswire.comSecurities Fraud Investigation Into Tandem Diabetes Care, Inc. (TNDM) Continues – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. CruzSeptember 30, 2025 | globenewswire.comCanaccord Genuity Maintains Tandem Diabetes Care (TNDM) Buy RecommendationSeptember 30, 2025 | msn.comCanaccord Genuity Group Reiterates Buy Rating for Tandem Diabetes Care (NASDAQ:TNDM)September 30, 2025 | americanbankingnews.comTandem t:slim X2 Insulin Pump Now Compatible With Lyumjev Ultra-Rapid Acting Insulin in the United StatesSeptember 29, 2025 | finance.yahoo.comTandem Diabetes Care (NASDAQ:TNDM) Earns Buy Rating from Canaccord Genuity GroupSeptember 29, 2025 | marketbeat.comRosen Law Firm Encourages Tandem Diabetes Care, Inc. Investors to Inquire About Securities Class Action Investigation - TNDMSeptember 28, 2025 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tandem Diabetes Care, Inc. - TNDMSeptember 28, 2025 | prnewswire.comAssenagon Asset Management S.A. Buys New Shares in Tandem Diabetes Care, Inc. $TNDMSeptember 28, 2025 | marketbeat.comTNDM Investor News: If You Have Suffered Losses in Tandem Diabetes Care, Inc. (NASDAQ: TNDM), You Are Encouraged to Contact The Rosen Law Firm About Your RightsSeptember 27, 2025 | globenewswire.comBanque Pictet & Cie SA Buys Shares of 84,028 Tandem Diabetes Care, Inc. $TNDMSeptember 27, 2025 | marketbeat.comWhy Tandem Diabetes (TNDM) Shares Are Trading Lower TodaySeptember 25, 2025 | msn.comTNDM Investor News: If You Have Suffered Losses in Tandem Diabetes Care, Inc. (NASDAQ: TNDM), You Are Encouraged to Contact The Rosen Law Firm About Your RightsSeptember 24, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSMTI, MDXG, TNDM, and INMD Company DescriptionsInMode NASDAQ:INMD$15.03 0.00 (-0.01%) As of 10:26 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions, as well as hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was incorporated in 2008 and is headquartered in Yokneam, Israel.MiMedx Group NASDAQ:MDXG$7.17 -0.09 (-1.27%) As of 10:26 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a barrier membrane allograft used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; and EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications. The company's products have applications in the areas of wound care, burn, surgical sectors of healthcare. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. was founded in 2006 and is headquartered in Marietta, Georgia.Sanara MedTech NASDAQ:SMTI$32.88 +2.55 (+8.41%) As of 10:25 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. It also provides BIAKOS Antimicrobial Skin and Wound Cleanser, a patented product that contains synergistic ingredients that have been shown to impact mature biofilm microbes; BIAKOS Antimicrobial Wound Gel, an antimicrobial hydrogel wound dressing that helps against planktonic microbes, as well as immature and mature biofilms; and BIAKOS Antimicrobial Skin and Wound Irrigation Solution. In addition, it develops BIASURGE, a no-rinse surgical solution used for wound irrigation; FORTIFY TRG, a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; FORTIFY FLOWABLE extracellular matrix, an advanced wound care device; TEXAGEN, a multi-layer amniotic membrane allograft used as an anatomical barrier with robust handling that can be sutured for securement; and VIM Amnion Matrix, a homologous wound covering product. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas.Tandem Diabetes Care NASDAQ:TNDM$14.83 +0.31 (+2.13%) As of 10:26 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs, and supported blood glucose meters; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Archer Aviation Stock Is Soaring—And What Comes Next Lithium Americas: Why This 31% Rally Is More Than Just a Headline AMD Could Double From Here—Thanks to Its Blockbuster OpenAI Deal EA’s $55 Billion Deal Spurs a Shake-Up in the Gaming Sector 3 Dividend Aristocrats to Buy Before Year’s End The Juice Is Loose: Why Plug Power's Rally Is Just the Beginning Joby's Stock Rallies as Public Flights Validate Global Game Plan SharkNinja Is Flashing a Buy Signal the Market Is Ignoring Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
